CRISPR 및 Cas 유전자 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 제품별, 서비스별, 용도별, 최종 용도별, 지역별 - 예측(2025-2034년)

The CRISPR & cas genes market size is expected to reach USD 21.46 billion by 2034, according to a new study by Polaris Market Research. The report "CRISPR & Cas Genes Market Size, Share, Trends, Industry Analysis Report By Product (Kits & Enzymes, Libraries), By Service, By Application, By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

CRISPR-Cas genes refer to a natural bacterial defense system used for gene editing. The CRISPR sequences guide the Cas enzyme to specific DNA locations to make precise cuts.

CRISPR gene editing offers a sustainable way to improve crops with increasing food demand and environmental challenges. It enables the development of pest-resistant, drought-tolerant, and higher-yielding plants without introducing foreign genes. This precision technology helps create healthier, more nutritious crops that meet consumer and regulatory preferences better than traditional genetically modified organisms (GMOs). Governments and agricultural companies invest heavily in CRISPR-based crop research to improve food security. The expanding use of gene editing in agriculture significantly boosts the demand for CRISPR enzymes, kits, and reagents, driving the market's growth worldwide.

Personalized medicine focuses on tailoring treatments based on an individual's unique genetic profile. CRISPR technology is crucial for developing gene therapies that target specific genetic mutations causing diseases. More patients seek personalized treatments that improve effectiveness and reduce side effects as awareness about genetic disorders rises. This trend fuels demand for CRISPR-based diagnostics and therapeutics, encouraging companies to invest in research and product development. The market grows as gene editing enables the creation of customized solutions for cancer, rare diseases, and inherited conditions, making personalized medicine a key driver in the CRISPR & Cas genes market.

CRISPR & Cas Genes Market Report Highlights

The kits & enzymes segment is projected to register a CAGR of 19.1% during the forecast period, owing to their essential role in facilitating gene-editing processes.

In 2024, the agricultural application segment captured 13.11% of the market revenue, driven by rising demand for improved crop traits such as pest resistance, drought tolerance, and higher yield, which is a key solution to global food security challenges.

North America led the CRISPR & Cas genes market in 2024, accounting for 45.52% of the global revenue, supported by a robust research ecosystem, significant financial backing, and a highly developed biotechnology sector.

The Asia Pacific CRISPR & Cas genes market is anticipated to expand at a CAGR of 19.3% during the forecast period, fueled by growing investments in biotechnology research and the strengthening of healthcare infrastructure.

A few global key market players are Addgene, AstraZeneca, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Danaher Corporation, Editas Medicine, Inc., Horizon Discovery Group Plc, Mammoth Biosciences, New England BioLabs, Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, ERS Genomics Ltd, Merck KGaA, Oxford Genetics Limited, and Sherlock Biosciences.

Polaris Market Research has segmented the CRISPR & Cas genes market report based on product, service, application, end use, and region:

By Product (Revenue - USD Billion, 2020-2034)

Kits & Enzymes

Vector-Based Cas

DNA-Free Cas

Libraries

Design Tool

Antibodies

Other Products

By Service (Revenue - USD Billion, 2020-2034)

Cell Line Engineering

gRNA Design

Microbial Gene Editing

DNA Synthesis

By Application (Revenue - USD Billion, 2020-2034)

Biomedical

Agricultural

By End Use (Revenue - USD Billion, 2020-2034)

Biotechnology & Pharmaceutical Companies

Academics & Government Research Institutes

Contract Research Organizations (CROs)

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

Chapter 1. Introduction

• 1.1 Report Description
  • 1.1.1 Objectives of the Study
  • 1.1.2 Market Scope
  • 1.1.3 Assumptions
• 1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

• 3.1 Overview
  • 3.1.1 Data Mining
• 3.2 Data Sources
  • 3.2.1 Primary Sources
  • 3.2.2 Secondary Sources

Chapter 4. CRISPR & Cas Genes Market Insights

• 4.1 CRISPR & Cas Genes - Industry snapshot
• 4.1 CRISPR & Cas Genes Market Dynamics
  • 4.1.1 Drivers and Opportunities
    • 4.1.1.1 Innovations in CRISPR technologies
    • 4.1.1.2 Applicability in varied areas
  • 4.1.2 Restraints and Challenges
    • 4.1.2.1 Inherent Disadvantages
• 4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers (Moderate)
  • 4.2.2 Threats of New Entrants: (Low)
  • 4.2.3 Bargaining Power of Buyers (Low to Medium)
  • 4.2.4 Threat of Substitute (Low)
  • 4.2.5 Rivalry among existing firms (Medium to High)
• 4.3 PEST Analysis
• 4.4 CRISPR & Cas Genes Market Industry trends
• 4.5 COVID-19 Impact Analysis

Chapter 5. Contact Point Information

• 5.1 Contact Point Information for obtaining a license to use the technology
  • 5.1.1 Wellcome Trust Sanger Institute, Cambridge, UK
  • 5.1.2 The Innovative Genomics Initiative, California
  • 5.1.3 Thermo Fisher Scientific, Waltham, Massachusetts
  • 5.1.4 the Broad Institute and Whitehead Institute
  • 5.1.5 ERS Genomics Ltd
  • 5.1.6 Merck KGaA
  • 5.1.7 Oxford Genetics Limited
  • 5.1.8 Caribou Biosciences, Inc.
  • 5.1.9 CRISPR Therapeutics
  • 5.1.10 Sherlock Biosciences
  • 5.1.11 UC Berkeley
• 5.2 The contract amount for genome editing technology

Chapter 6. CRISPR & Cas Genes Market Assessment by Product & Services

• 6.1 Introduction
• 6.2 Product
  • 6.2.1 Kits & Enzymes
    • 6.2.1.1 Vector-based Cas
    • 6.2.1.2 DNA-free Cas
  • 6.2.2 Libraries
  • 6.2.3 Design Tool
  • 6.2.5 Other Products
• 6.3 Services
  • 6.3.1 Cell Line Engineering
  • 6.3.2 gRNA Design
  • 6.3.3 Microbial Gene Editing
  • 6.3.4 DNA Synthesis

Chapter 7. CRISPR & Cas Genes Market Assessment by Application

• 7.1 Introduction
• 7.2 Biomedical
• 7.3 Agricultural

Chapter 8. CRISPR & Cas Genes Market Assessment by End-Use

• 8.1 Introduction
• 8.2 Biotechnology & Pharmaceutical Companies
• 8.3 Academics & Government Research Institutes
• 8.4 Contract Research Organizations (CROs)

Chapter 9. CRISPR & Cas Genes Market Assessment by Region

• 9.1 Introduction
• 9.2 CRISPR & Cas Genes Market - North America
  • 9.2.1 CRISPR & Cas Genes Market - U.S.
  • 9.2.2 CRISPR & Cas Genes Market - Canada
• 9.3 CRISPR & Cas Genes Market - Europe
  • 9.3.1 CRISPR & Cas Genes Market - Germany
  • 9.3.2 CRISPR & Cas Genes Market - UK
  • 9.3.3 CRISPR & Cas Genes Market - France
  • 9.3.4 CRISPR & Cas Genes Market - Italy
  • 9.3.5 CRISPR & Cas Genes Market - Spain
  • 9.3.6 CRISPR & Cas Genes Market - Netherlands
  • 9.3.7 CRISPR & Cas Genes Market - Austria
• 9.4 CRISPR & Cas Genes Market - Asia Pacific
  • 9.4.1 CRISPR & Cas Genes Market - China
  • 9.4.2 CRISPR & Cas Genes Market - India
  • 9.4.3 CRISPR & Cas Genes Market - Japan
  • 9.4.4 CRISPR & Cas Genes Market - South Korea
• 9.5 CRISPR & Cas Genes Market - Latin America
  • 9.5.1 CRISPR & Cas Genes Market - Brazil
  • 9.5.2 CRISPR & Cas Genes Market - Mexico
  • 9.5.3 CRISPR & Cas Genes Market - Argentina
• 9.6 CRISPR & Cas Genes Market - Middle East & Africa
  • 9.6.1 CRISPR & Cas Genes Market - Saudi Arabia
  • 9.6.2 CRISPR & Cas Genes Market - UAE

Chapter 10. Competitive Landscape

• 10.1 Product Launch & Collaborations Both Are The Best Adopted Strategies by the Companies
• 10.2 Product Launch
• 10.3 Partnerships/Collaborations/Agreements/Exhibitions

Chapter 11. The Company Profiles

• 11.1 Addgene
  • 11.1.1 Business Overview
  • 11.1.2 Financial Snapshot
  • 11.1.3 Products and Services
• 11.2 AstraZeneca
  • 11.2.1 Business Overview
  • 11.2.2 Financial Snapshot
  • 11.2.3 Products and Services
  • 11.2.4 Recent Developments
• 11.3 Caribou Biosciences, Inc.
  • 11.3.1 Business Overview
  • 11.3.2 Financial Snapshot
  • 11.3.3 Products and Services
  • 11.3.4 Recent Developments
• 11.4 Cellectis
  • 11.4.1 Business Overview
  • 11.4.2 Financial Snapshot
  • 11.4.3 Products and Services
  • 11.4.4 Recent Developments
• 11.5 CRISPR Therapeutics
  • 11.5.1 Business Overview
  • 11.5.2 Financial Snapshot
  • 11.5.3 Products and Services
  • 11.5.4 Recent Developments
• 11.6 Danaher Corporation
  • 11.6.1 Business Overview
  • 11.6.2 Financial Snapshot
  • 11.6.3 Products and Services
  • 11.6.4 Recent Developments
• 11.7 Editas Medicine, Inc.
  • 11.7.1 Business Overview
  • 11.7.2 Financial Snapshot
  • 11.7.3 Products and Services
• 11.8 Horizon Discovery Group Plc
  • 11.8.1 Business Overview
  • 11.8.2 Financial Snapshot
  • 11.8.3 Products and Services
  • 11.8.4 Recent Developments
• 11.9 Mammoth Biosciences
  • 11.9.1 Business Overview
  • 11.9.2 Financial Snapshot
  • 11.9.3 Products and Services
• 11.10 New England BioLabs
  • 11.10.1 Business Overview
  • 11.10.2 Financial Snapshot
  • 11.10.3 Products and Services